G1 THERAPEUTICS
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the lives of those impacted by cancer. It is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types.
G1 THERAPEUTICS
Industry:
Biotechnology Developer Platform Medical Therapeutics
Founded:
2008-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.g1therapeutics.com
Total Employee:
101+
Status:
Active
Contact:
+1 919 213 9835
Email Addresses:
[email protected]
Total Funding:
497.32 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Apache Microsoft Exchange Online Amazon
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - G1 Therapeutics
Tavistock Life Sciences
Tavistock Life Sciences investment in Series C - G1 Therapeutics
Franklin Templeton Investments
Franklin Templeton Investments investment in Series C - G1 Therapeutics
Cowen Group
Cowen Group investment in Series C - G1 Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - G1 Therapeutics
Eshelman Ventures
Eshelman Ventures investment in Series C - G1 Therapeutics
Aju IB Investment
Aju IB Investment investment in Series C - G1 Therapeutics
Hatteras Venture Partners
Hatteras Venture Partners investment in Series C - G1 Therapeutics
Mountain Group Capital
Mountain Group Capital investment in Series C - G1 Therapeutics
Lumira Ventures
Lumira Ventures investment in Series C - G1 Therapeutics
Key Employee Changes
Official Site Inspections
http://www.g1therapeutics.com Semrush global rank: 3.87 M Semrush visits lastest month: 3.34 K
- Host name: ec2-54-176-110-96.us-west-1.compute.amazonaws.com
- IP address: 54.176.110.96
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95141
More informations about "G1 Therapeutics"
G1 Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 919 213 9835 G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.See details»
G1 Therapeutics, Inc. - Dun & Bradstreet
Company Description: G1 Therapeutics is a biopharmaceutical firm working to develop and delivery of next generation therapies that improve the lives of people affected by cancer. The …See details»
G1 Therapeutics, Inc. | LinkedIn
G1 Therapeutics, Inc. | 16,504 followers on LinkedIn. Our mission is to discover, develop and deliver next generation cancer therapies. | G1 Therapeutics, Inc. is a wholly owned subsidiary of ...See details»
Pharmacosmos Group to Acquire G1 Therapeutics - Morningstar
Aug 7, 2024 By combining our existing colleagues with the great team at G1 Therapeutics, we will meaningfully expand our organization serving oncologists in the US. This will enable …See details»
Pharmacosmos Group and G1 Therapeutics Announce …
Sep 18, 2024 Following the closing of the tender offer, on September 18, 2024 Purchaser merged with and into G1 Therapeutics, with G1 Therapeutics continuing as the surviving corporation and a wholly owned ...See details»
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The
Feb 13, 2021 A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com. The webcast will be archived on the same page for 90 days ...See details»
G1 Therapeutics Announces Appointment of Andrew Perry as …
Aug 2, 2021 Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 …See details»
G1 Therapeutics Announces Chief Executive Officer - GlobeNewswire
Sep 30, 2020 - Mark Velleca, M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors - Jack...See details»
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan ...
Jan 3, 2024 RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced …See details»
G1 Therapeutics Provides First Quarter 2020 Corporate and …
Mar 31, 2020 The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 5669692. A live and archived webcast …See details»
G1 Therapeutics Announces Chief Executive Officer Succession Plan
Sep 30, 2020 G1 Therapeutics, Inc. (Nasdaq: GTHX), a company whose mission is to deliver innovative therapies that improve the lives of people with cancer, today announced that …See details»
G1 Therapeutics Announces Chief Executive Officer Succession Plan
Sep 30, 2020 - Mark Velleca, M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors - Jack Bailey to succeed Dr. Velleca …See details»
G1 Therapeutics Announces Upcoming Presentation at the 2024 …
May 23, 2024 RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced …See details»
G1 Therapeutics Provides Corporate Update at the 42nd
Jan 8, 2024 G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference. ...See details»
G1 Therapeutics Announces Acceptance and Priority Review of …
Aug 17, 2020 For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics. Forward-Looking Statements This press release contains forward …See details»
Pharmacosmos Group to Acquire G1 Therapeutics - Yahoo Finance
Aug 7, 2024 - Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1’s COSELA® (trilaciclib), the First and …See details»
Recommended Stories - Yahoo Finance
Jun 24, 2024 - PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its …See details»
G1 Therapeutics Announces Acceptance and Priority Review of …
Aug 17, 2020 \- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration \- Priority Review for trilaciclib is based on positive data from three randomized …See details»
G1 Therapeutics Provides First Quarter 2022 Financial Results and ...
May 4, 2022 The live call may be accessed by dialing (866) 763-6020 (domestic) or (409) 216-0626 (international) and entering the conference code: 2229795. A live and archived webcast …See details»